Abstract Library

#4424 Tumour-derived apolipoprotein E induces tip endothelial cell to remodel tumour stroma ratio and promote pancreatic neuroendocrine tumour progression

Introduction: Current clinical trials have shown that single-targeted matrix administration does not improve patient prognosis. The investigation of targeted matrix administration in combination with other therapies is crucial for effectively managing TSR in pNETs.

Conference:

Presenting Author: Ji S

Authors: Lou X, Ji S, Xu X, Chen J, Yu X,

Keywords: APOE, pancreatic neuroendocrine tumour, endothelial cell, tumour stroma ratio, mTOR inhibitor,

#4396 Hypoxic microenvironment in neuroendocrine tumours

Introduction: The hypoxic microenvironment is a hallmark of many solid tumours, including neuroendocrine tumours (NETs). Hypoxia plays a crucial role in tumour progression, metastasis, and therapy resistance. However, the specific mechanisms by which hypoxia influences NET behaviour remain poorly understood.

Conference:

Presenting Author:

Authors: Xu L, Yu P, Ye M, Chen J, Tang Q,

Keywords: Neuroendocrine tumour, hypoxia, HIF-1α, VEGF, mTOR, PI3K/AKT, drug resistance, EMT,

#4395 Mechanisms of drug resistance in neuroendocrine tumours: A basic research study

Introduction: Neuroendocrine tumours (NETs) often show resistance to chemotherapy and targeted therapies, leading to treatment failure. However, the molecular mechanisms underlying this resistance remain poorly understood.

Conference:

Presenting Author:

Authors: Xu L, Yu P, Chen J, Ye M, Xue B,

Keywords: Neuroendocrine tumour, drug resistance, mTOR, PI3K/AKT, tumour microenvironment, chemotherapy,

#4319 Everolimus combined with orlistat inhibits the development of neuroendocrine tumours by inhibiting the mTOR-PI3K-Akt signalling pathway

Introduction: Everolimus, an mTOR inhibitor, has demonstrated efficacy in NET treatment. Orlistat, used primarily for obesity management, inhibits fat absorption. This study investigates the potential synergistic effects of Everolimus combined with Orlistat on the development of NETs.

Conference:

Presenting Author:

Authors: Xu L, Tang Q, Ye M,

Keywords: Everolimus, orlistat, mTOR, PI3K/Akt, signalling pathway,

#4316 Combination of sorafenib and everolimus regresses pancreatic neuroendocrine tumour significantly in vitro and vivo

Introduction: PNET is a rare group of highly heterogeneous tumours with neuroendocrine differentiation properties. Everolimus is the most promising drug for progressive well-differentiated pNETs. Sorafenib's anti-tumour activity may involve regulation of the mTOR pathway.

Conference:

Presenting Author: Zheng H

Authors: Zheng H,

Keywords: sorafenib, everolimus, pancreatic neuroendocrine tumour, mTOR,